Nag Nivedita, Dutta Samikshan
Department of Microbiology, Sister Nibedita Government General Degree College for Girls, Kolkata 700027, India.
Department of Biochemistry and Molecular Biology, University of Nebraska Medical Center, Omaha, NE 68198-5870, USA.
J Cancer Metastasis Treat. 2020;6. doi: 10.20517/2394-4722.2020.23. Epub 2020 Jun 18.
Prostate cancer (PCa) is the leading cause of cancer death in men. With more therapeutic modalities available, the overall survival in PCa has increased significantly in recent years. Patients with relapses after advanced secondgeneration anti-androgen therapy however, often show poor disease prognosis. This group of patients often die from cancer-related complicacies. Multiple approaches have been taken to understand disease recurrence and to correlate the gene expression profile. In one such study, an 11-gene signature was identified to be associated with PCa recurrence and poor survival. Amongst them, a specific deubiquitinase called ubiquitin-specific peptidase 22 (USP22) was selectively and progressively overexpressed with PCa progression. Subsequently, it was shown to regulate androgen receptors and Myc, the two most important regulators of PCa progression. Furthermore, USP22 has been shown to be associated with the development of therapy resistant PCa. Inhibiting USP22 was also found to be therapeutically advantageous, especially in clinically challenging and advanced PCa. This review provides an update of USP22 related functions and challenges associated with PCa research and explains why targeting this axis is beneficial for PCa relapse cases.
前列腺癌（PCa）是男性癌症死亡的主要原因。随着越来越多治疗方式的出现，近年来PCa患者的总生存率显著提高。然而，接受先进的第二代抗雄激素治疗后复发的患者，往往显示出较差的疾病预后。这组患者常死于癌症相关并发症。人们采取了多种方法来了解疾病复发情况，并将基因表达谱与之关联。在一项此类研究中，一个11基因特征被确定与PCa复发和不良生存相关。其中，一种名为泛素特异性肽酶22（USP22）的特定去泛素化酶随着PCa进展而选择性地、逐步地过度表达。随后，研究表明它能调节雄激素受体和Myc，这是PCa进展的两个最重要调节因子。此外，USP22已被证明与抗治疗性PCa的发展有关。抑制USP22在治疗上也被证明是有益的，尤其是在具有临床挑战性的晚期PCa中。本综述提供了与PCa研究相关的USP22功能及挑战的最新情况，并解释了为何针对这一轴对PCa复发病例有益。
